Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
4.210
-0.140 (-3.22%)
At close: Jul 25, 2025, 4:00 PM
4.200
-0.010 (-0.24%)
After-hours: Jul 25, 2025, 7:53 PM EDT
Prime Medicine Revenue
Prime Medicine had revenue of $1.45M in the quarter ending March 31, 2025, with 146.02% growth. This brings the company's revenue in the last twelve months to $3.85M, up 550.76% year-over-year. In the year 2024, Prime Medicine had annual revenue of $2.98M.
Revenue (ttm)
$3.85M
Revenue Growth
+550.76%
P/S Ratio
137.06
Revenue / Employee
$17,972
Employees
214
Market Cap
551.61M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
Novartis AG | 55.19B |
AstraZeneca | 54.98B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
PRME News
- 9 days ago - Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy - Business Wire
- 9 days ago - Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis - GlobeNewsWire
- 18 days ago - Prime Medicine: Pressing Forward With Lead Liver Targeting Indications - Seeking Alpha
- 2 months ago - Prime Medicine to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition - GlobeNewsWire
- 2 months ago - Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease - GlobeNewsWire
- 2 months ago - Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 4 months ago - Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewsWire